Coronary Artery Disease
Conditions
Keywords
HeartMate PHP, High Risk PCI, Mechanical circulatory support device, MCS, Abbott, SJM-CIP-10148
Brief summary
The HeartMate PHP System is a temporary (\<6 hours) ventricular assist device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac surgeon, has determined high-risk PCI is the appropriate therapeutic option. Use of the HeartMate PHP Systems in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri-and post-procedural adverse events.
Detailed description
Prospective, randomized, multi-center, open-label trial of the HeartMate PHP at up to 120 sites in the United States (U.S.). Control device will be any Abiomed Impella device approved for use in high-risk PCI. This clinical investigation is divided into two phases, a feasibility phase and a pivotal phase. * Feasibility Phase: Includes 75 roll-in and 120 randomized subjects registered under the clinical investigational plan (CIP) versions 2-4 at 48 sites in the U.S. prior to January 30, 2017 * Pivotal Phase: Includes subjects to be registered under Version F or a later version of the CIP at up to 120 sites in the U.S. Non-randomized Roll-in Cohort: Up to 480 subjects with the HeartMate PHP. Randomized Cohort: A minimum of 473 and a maximum of 716 subjects will be randomized in a 2:1 ratio to the HeartMate PHP and Impella.
Interventions
DEVICEHeartMate PHP
The HeartMate PHP System is a temporary (\<6 hours) ventricular assist device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac surgeon, has determined high-risk PCI is an acceptable therapeutic option. Use of the HeartMate PHP Systems in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri-and post-procedural adverse events.
DEVICEAny Abiomed Impella® device approved for use in high-risk PCI
Any Abiomed Impella® device approved for use in high-risk PCI.
Sponsors
Abbott Medical Devices
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* At least 18 years of age * Subject is undergoing elective or urgent high-risk PCI procedure and is hemodynamically stable * Subject is indicated for a revascularization of at least one de novo or restenotic lesion in a native coronary vessel or bypass graft * A heart team, including a cardiac surgeon, has determined high risk PCI is an acceptable therapeutic option * Subject must provide written informed consent prior to any clinical investigation related procedure Imaging Inclusion Criteria: • The presence of complex coronary artery disease (CAD) makes hemodynamic instability resulting from repeat episodes of reversible myocardial ischemia during PCI likely. Complex CAD is defined as an ejection fraction of \<50% by echocardiographic assessment AND at least one of the following: * intervention of the last patent coronary conduit, OR * intervention of an unprotected left main artery, OR * intervention on patient presenting with triple vessel disease defined as at least one significant stenosis (at least 50% diameter stenosis on visual assessment) in all three major epicardial territories
Exclusion criteria
* Emergency PCI * Any prior coronary revascularization within the last 6 months * Any MI with elevated cardiac biomarker (creatinine kinase-MB (CK-MB) or troponin \>1X upper limit of normal (ULN)) and no evidence of at least 1 consecutive CK-MB or troponin value trending downward from previous value (at least 4 hours apart) OR ST Elevation MI (STEMI) within 72 hours prior to the index procedure regardless of the level of cardiac biomarker * Cardiac arrest within 24 hours of procedure requiring cardiopulmonary resuscitation (CPR) or defibrillation * Any use of a mechanical circulatory support device within 14 days prior to the index procedure (Note: Subjects must be hemodynamically stable without any hemodynamic support to be eligible for this clinical investigation.) * Hemodynamic support with a mechanical circulatory support device (e.g.,the HeartMate PHP, Impella, intra-aortic balloon pump (IABP), or extracorporeal membrane oxygenation (ECMO)), post-PCI is anticipated * Any condition that requires discontinuation of antiplatelet and/or anticoagulant therapy within 90 days following the index procedure (e.g., planned noncardiac surgery) * Any use of vasopressors or inotropes within 24 hours prior to the index procedure * Staged PCI is planned within 90 days following device removal * Cardiogenic shock (SBP \<90 mmHg for \>1 hour with either cool clammy skin OR oliguria OR altered sensorium AND cardiac index \<2.2 L/min/m\^2) * History of aortic valve replacement or repair * Severe peripheral vascular disease that will preclude the use of a 14F access sheath, which is required for the insertion of the HeartMate PHP catheter (If the investigator is unsure of the presence or severity of the peripheral vascular diseases for study device access, an appropriate imaging assessment (e.g., duplex ultrasound, angiogram or computerized tomography) should be performed to verify the access before randomization.) * Known abnormalities of the aorta that would preclude surgery, including aneurysms and significant tortuosity or calcifications * Subject is on hemodialysis * Liver dysfunction with elevation of liver enzymes and bilirubin levels to ≥ 3X ULN or Internationalized Normalized Ratio (INR) ≥1.6 or lactate dehydrogenase (LDH) \> 2.5X ULN * Abnormal coagulation parameters (platelet count ≤75000/mm\^3 or INR ≥1.6 or fibrinogen ≤1.5 g/l) * Active systemic infection requiring treatment with antibiotics * Subject had active COVID-19 symptoms and/or a positive test result within the prior 2 months * Stroke or transient ischemic attack (TIA) within 6 months of procedure * Any allergy or intolerance to ionic and nonionic contrast media, anticoagulants (including heparin), or antiplatelet therapy drugs that cannot be adequately premedicated * Subject is pregnant (For a female subject of childbearing potential, a pregnancy test must be performed within 14 days (≤14 days) prior to the index procedure per site standard test) * Participation in another clinical study of an investigational drug or device that has not met its primary endpoint * Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with followup requirements, or impact the scientific soundness of the clinical investigation results * Life expectancy \<1 year Imaging
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of Participants With Composite of Cardiovascular Death, Myocardial Infarction, Stroke, Any Unplanned Repeat Revascularization (PCI/CABG), Bleeding (BARC 3/5) up to 14 Days Post-device Removal, Severe Hypotension, and Change in Aortic Insufficiency | 90 Days | The primary endpoint, including the following components representing important safety and effectiveness endpoints will be evaluated using the difference in event rates in the ITT population. * Cardiovascular Death * Myocardial infarction (MI) * Stroke * Any unplanned repeat revascularization (PCI or CABG) * Bleeding (BARC 3 or 5) up to 14 days post-device removal * Severe hypotension, defined as: systolic blood pressure (SBP) or augmented diastolic pressure (whichever is greater) \<90 mmHg while on device support requiring (1) more than one administration of OR (2) continuous infusion of inotropic/pressor medications to restore hemodynamics * Change in aortic insufficiency from baseline to 90 days by echocardiographic assessment. |
Countries
United States
Participant flow
Recruitment details
A total of 18 PHP roll-in and 36 randomized subjects were registered at 15 sites in the pivotal phase of the study.
Participants by arm
| Arm | Count |
|---|---|
| HeartMate PHP (Roll-in) Participants who receive a HeartMate PHP device without randomisation will be included in this arm
HeartMate PHP: The HeartMate PHP System is a temporary (\<6 hours) ventricular assist device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac surgeon, has determined high-risk PCI is an acceptable therapeutic option. Use of the HeartMate PHP Systems in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri-and post-procedural adverse events. | 18 |
| HeartMate PHP (Randomised) Participants who receive a HeartMate PHP device after randomisation will be included in this arm
HeartMate PHP: The HeartMate PHP System is a temporary (\<6 hours) ventricular assist device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac surgeon, has determined high-risk PCI is an acceptable therapeutic option. Use of the HeartMate PHP Systems in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri-and post-procedural adverse events. | 26 |
| Any Abiomed Impella® (Randomised) Participants who receive any Abiomed Impella® Device approved for use in high-risk PCI after randomisation will be included in this arm
Any Abiomed Impella® device approved for use in high-risk PCI: Any Abiomed Impella® device approved for use in high-risk PCI. | 10 |
| Total | 54 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Death | 2 | 1 | 0 |
| Overall Study | Lost to Follow-up | 1 | 2 | 2 |
| Overall Study | Withdrawal by Subject | 0 | 1 | 1 |
Baseline characteristics
| Characteristic | HeartMate PHP (Roll-in) | HeartMate PHP (Randomised) | Any Abiomed Impella® (Randomised) | Total |
|---|---|---|---|---|
| Age, Continuous | 73.3 years STANDARD_DEVIATION 8.7 | 67.8 years STANDARD_DEVIATION 8.8 | 72.2 years STANDARD_DEVIATION 6.7 | 70.5 years STANDARD_DEVIATION 8.7 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants | 5 Participants | 1 Participants | 8 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 15 Participants | 14 Participants | 6 Participants | 35 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants | 7 Participants | 3 Participants | 11 Participants |
| Percutaneous Coronary Intervention (PCI) | 12 Participants | 11 Participants | 6 Participants | 29 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 1 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 4 Participants | 3 Participants | 8 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants | 0 Participants | 1 Participants | 4 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 4 Participants | 1 Participants | 6 Participants |
| Race (NIH/OMB) White | 12 Participants | 17 Participants | 4 Participants | 33 Participants |
| Region of Enrollment United States | 18 Participants | 26 Participants | 10 Participants | 54 Participants |
| Sex: Female, Male Female | 3 Participants | 5 Participants | 2 Participants | 10 Participants |
| Sex: Female, Male Male | 15 Participants | 21 Participants | 8 Participants | 44 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 2 / 18 | 1 / 26 | 0 / 10 |
| other Total, other adverse events | 8 / 18 | 8 / 26 | 3 / 10 |
| serious Total, serious adverse events | 5 / 18 | 9 / 26 | 5 / 10 |
Outcome results
Primary
Rate of Participants With Composite of Cardiovascular Death, Myocardial Infarction, Stroke, Any Unplanned Repeat Revascularization (PCI/CABG), Bleeding (BARC 3/5) up to 14 Days Post-device Removal, Severe Hypotension, and Change in Aortic Insufficiency
The primary endpoint, including the following components representing important safety and effectiveness endpoints will be evaluated using the difference in event rates in the ITT population. * Cardiovascular Death * Myocardial infarction (MI) * Stroke * Any unplanned repeat revascularization (PCI or CABG) * Bleeding (BARC 3 or 5) up to 14 days post-device removal * Severe hypotension, defined as: systolic blood pressure (SBP) or augmented diastolic pressure (whichever is greater) \<90 mmHg while on device support requiring (1) more than one administration of OR (2) continuous infusion of inotropic/pressor medications to restore hemodynamics * Change in aortic insufficiency from baseline to 90 days by echocardiographic assessment.
Time frame: 90 Days
Population: The number of participants analyzed includes subjects who were available at that time of analysis
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| HeartMate PHP (Roll-in) | Rate of Participants With Composite of Cardiovascular Death, Myocardial Infarction, Stroke, Any Unplanned Repeat Revascularization (PCI/CABG), Bleeding (BARC 3/5) up to 14 Days Post-device Removal, Severe Hypotension, and Change in Aortic Insufficiency | 29.4 percentage of participants |
| HeartMate PHP (Randomised) | Rate of Participants With Composite of Cardiovascular Death, Myocardial Infarction, Stroke, Any Unplanned Repeat Revascularization (PCI/CABG), Bleeding (BARC 3/5) up to 14 Days Post-device Removal, Severe Hypotension, and Change in Aortic Insufficiency | 19.0 percentage of participants |
| Any Abiomed Impella® (Randomised) | Rate of Participants With Composite of Cardiovascular Death, Myocardial Infarction, Stroke, Any Unplanned Repeat Revascularization (PCI/CABG), Bleeding (BARC 3/5) up to 14 Days Post-device Removal, Severe Hypotension, and Change in Aortic Insufficiency | 50.0 percentage of participants |